Lumida
/ISPR
⌘K
Ispire Technology Inc

Ispire Technology Inc

ISPR
$1.75USD↓-6.91%-0.13 today

MARKET CAP

100.4M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$1
$4

AI Summary

Stalk
Buy NowMedium

Following an early Stage 1 consolidation, price has formed higher highs and higher lows above rising short-term EMAs, signaling medium-term bullish asymmetry despite a longer-term downtrend. The recent pullback held just above the 9/21 EMA zone, offering a structurally favorable entry on continued repair. Execution is now justified in small size with stops keyed to EMA support, while long-term bearish pressure remains a monitorable risk.

  • ↑OpEx down 39% YoY to $5.9M, improving cost structure
  • ↑Cash reserves rose to $18M, targeting cash flow positivity by H2 2026
  • ↓Q3 revenue fell 28% YoY to $18.7M with 10.7% gross margin
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

iSpire Technologies (NASDAQ: ISPR) is an evolving player in the vaping and nicotine compliance technology space, focusing on manufacturing and regulatory solutions. The company aims to capitalize on emerging opportunities within the nicotine market while distancing itself from its previous cannabis operations, ultimately positioning itself to innovate and lead in the sector with strategic manufacturing advantages, specifically leveraging its new facility in Malaysia.

Bull says

  • ↑OpEx down 39% YoY to $5.9M, improving cost structure
  • ↑Cash reserves rose to $18M, targeting cash flow positivity by H2 2026
  • ↑Malaysia facility offers a 25% tariff advantage over China
  • ↑Pivot to high-quality nicotine clients aims to boost margins and cash
  • ↑Age-gating tech positions iSpire for flavored nicotine approvals
  • ↑Strong factor profile and rate sensitivity suggest undervaluation

Bear says

  • ↓Q3 revenue fell 28% YoY to $18.7M with 10.7% gross margin
  • ↓Net loss of $9.5M persists despite reduction from $10.9M
  • ↓Weak profitability metrics and negative earnings yield challenge valuation
  • ↓Poor liquidity profile and working capital risks may pressure operations
  • ↓FDA approval delays for age-gating tech could stall growth
  • ↓Minimal institutional ownership and high volatility signal skepticism

Earnings Call · Q3 2025 · Mgmt. Guidance

Updated 05-29-2026neutral

Transcript signals

Bull points

  • four looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
  • during the quarter, we were able to reduce our account receivable by approximately $7.3 million from the previous quarter to approximately $60.4 million. This includes a reduction in the underlining account receivable balance of approximately $2.6 million, reverting the trend we have seen with the increase in account receivable during previous quarters.
  • We expect to continue making more progress on reducing our account receivable in the coming quarters as we focus on higher quality and the larger customers with improved payment terms.

Bear points

  • For the third quarter of fiscal 2025, total revenue decreased to 26.2 million, representing a change of 12.7% or 3.8 million compared to 30 million in the same period last year.
  • Revenue from North America of approximately 8.8 million in Q3 fiscal 2025 represented a decline of 3.6 million or 28.9% compared to 12.4 million for the third quarter in fiscal 2024.
  • Asia-Pacific revenues of approximately 3 million represented a decline of 0.8 million or 21.4% compared to 3.8 million in the third quarter of last fiscal year.
Read full transcript analysis ›